

Ref. No. JPL/CS/2155/2025

Date: 28th January, 2025.

To
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Script Code :524731

Sub: Integrated Filing (Financial) for the quarter and nine-months ended on 31st December, 2024

Dear Sir/ Madam,

In accordance with the SEBI Circular No. SEBI/HO/CFD/CFD-PoD2/CIR/P/2024/185 dated 31st December, 2024, the Integrated Filing (Financial) for the quarter and nine months ended on 31st December, 2024 is enclosed herewith.

The above information is also available on website of the Company at www.jenburkt.com.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Limited,



ASHISH R. SHAH
Company Secretary and Compliance Officer

Encl.: As Stated Above.

Statement of Standalone Unaudited Financial Results for the Quarter & Nine Months Ended on 31st December, 2024

(Rs. in Lacs other than EPS)

	Particulars	Quarter Ended			Year to Date		Year Ended
		31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	3689.30	4121.59	3565.98	11064.46	10312.45	14196.65
II	Other Income	158.18	185.33	134.56	484.08	347.82	466.69
III	Total income (I + II)	3847.48	4306.92	3700.54	11548.54	10660.27	14663.34
IV	Expenses						
	(a) Cost of Materials Consumed	224.34	214.53	215.20	622.64	587.45	839.18
	(b) Purchase of Stock-in-trade	493.42	532.82	502.21	1601.47	1735.34	2241.24
	(c) Changes in inventories of Finished Goods, Stock-in-trade and WIP	0.87	80.42	28.07	-48.71	-102.61	-39.29
	(d) Employee benefit expenses	1091.58	1251.90	1155.66	3410.24	3211.10	4248.85
	(e) Finance Costs	11.03	11.64	7.03	34.15	21.27	27.07
	(f) Depreciation and Amortisation Expense	77.86	63.90	62.96	193.66	172.12	233.95
	(g) Other expenses	997.05	899.43	945.37	2525.35	2554.50	3594.75
	Total Expenses (IV)	2896.15	3054.64	2916.50	8338.80	8179.17	11145.75
V	Profit before tax (III - IV)	951.33	1252.28	784.04	3209.74	2481.10	3517.59
VI	Tax Expense						
	(i) Current Tax	300.00	300.00	250.00	850.00	700.00	963.50
	(ii) Income Tax for previous years	0.00	0.00	0.00	0.00	6.81	8.45
	(iii) Deferred Tax	0.58	-7.77	-6.40	7.34	-35.25	-52.09
VII	Profit after tax for the period (V-VI)	650.75	960.05	540.44	2352.40	1809.54	2597.73
VIII	Other Comprehensive Income						
A	(i) Items that will not be reclassified to profit or loss	-66.16	78.59	120.58	186.03	293.22	314.83
	(ii) Income Tax relating to Items that will not be reclassified to profit or loss	8.56	21.93	-14.27	11.97	-18.68	-21.99
B	(i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
IX	Total Comprehensive Income for the period (VII + VIII)	593.16	1060.57	646.75	2550.40	2084.08	2890.57
	Paid up Equity Share Capital (F.V. Rs.10/- each)	441.33	441.33	441.33	441.33	441.33	441.33
X	Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted	14.75	21.75	12.25	53.30	41.00	58.86

Notes:

- The above statement of standalone unaudited financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 28th January, 2025.
- The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.

For Jenburkt Pharmaceuticals Ltd.



(Ashish U. Bhuta)

Chairman & Managing Director

(DIN No: 00226479)

Place : Mumbai

Date : January 28, 2025


Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai

D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9TH FLOOR, TARDEO CIRCLE, MUMBAI - 400034

TEL: 23513758 / 23520330 FAX: 66607263, 9322508373

Email ID: info@drmehta.in, vikram@drmehta.in, ashok@drmehta.in

Limited Review Report on Unaudited Quarterly Standalone Financial Results of Jenburkt Pharmaceuticals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015

To the Board of Directors of

Jenburkt Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited standalone financial results of JENBURKT PHARMACEUTICALS LTD for the quarter ended 31st December 2024 ('the statement').


This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For D.R.Mehta & Associates,
Chartered Accountants
(Firm Reg. No. 106207W)


Partner

Vikram Mehta
(Membership No. 047347)

UDIN: 25047347BMKQFC3975

Place: Mumbai

Date: 28th January 2025



B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. – **Not Applicable**

C. Format for disclosing outstanding default on loans and debt securities –

S. No.	Particulars	₹
1.	Loans / revolving facilities like cash credit from banks / financial institutions	
A	Total amount outstanding as on date	0
B	Of the total amount outstanding, amount of default as on date	0
2.	Unlisted debt securities i.e. NCDs and NCRPS	
A	Total amount outstanding as on date	0
B	Of the total amount outstanding, amount of default as on date	0
3	Total financial indebtedness of the listed entity including short-term and long-term debt	0

D. Format for disclosure of related party transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) – **Not Applicable**

E. Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (standalone and consolidated separately) (applicable only for annual filing i.e., 4th quarter) – **Not Applicable**

